Expression of a Disintegrin and Metalloprotease (ADAM and ADAMTS) Enzymes in Human Non-small-cell Lung Carcinomas (NSCLC)

Overview

Journal Br J Cancer

Specialty Oncology

Date 2006 Feb 24

PMID 16495931

Citations 39

Authors

N Rocks

G Paulissen

F Quesada Calvo

M Polette

M Gueders

C Munaut

J-M Foidart

A Noel

P Birembaut

D Cataldo

Affiliations

Soon will be listed here.

Abstract

A Disintegrin and Metalloprotease (ADAM) are transmembrane proteases displaying multiple functions. ADAM with ThromboSpondin-like motifs (ADAMTS) are secreted proteases characterised by thrombospondin (TS) motifs in their C-terminal domain. The aim of this work was to evaluate the expression pattern of ADAMs and ADAMTS in non small cell lung carcinomas (NSCLC) and to investigate the possible correlation between their expression and cancer progression. Reverse transcriptase-polymerase chain reaction (RT-PCR), Western blot and immunohistochemical analyses were performed on NSCLC samples and corresponding nondiseased tissue fragments. Among the ADAMs evaluated (ADAM-8, -9, -10, -12, -15, -17, ADAMTS-1, TS-2 and TS-12), a modulation of ADAM-12 and ADAMTS-1 mRNA expression was observed. Amounts of ADAM-12 mRNA transcripts were increased in tumour tissues as compared to the corresponding controls. In sharp contrast, ADAMTS-1 mRNA levels were significantly lower in tumour tissues when compared to corresponding nondiseased lung. These results were corroborated at the protein level by Western blot and immunohistochemistry. A positive correlation was observed between the mRNA levels of ADAM-12 and those of two vascular endothelial growth factor (VEGF)-A isoforms (VEGF-A(165) and VEGF-A(121)). Taken together, these results providing evidence for an overexpression of ADAM-12 and a lower expression of ADAMTS-1 in non-small-cell lung cancer suggest that these proteases play different functions in cancer progression.

Citing Articles

Decoding tumor heterogeneity in uveal melanoma: basement membrane genes as novel biomarkers and therapeutic targets revealed by multi-omics approaches for cancer immunotherapy.

Li Y, Cai H, Yang J, Xie X, Pei S, Wu Y Front Pharmacol. 2023; 14:1264345.

PMID: 37822877 PMC: 10562578. DOI: 10.3389/fphar.2023.1264345.

The emerging roles of lysine-specific demethylase 4A in cancer: Implications in tumorigenesis and therapeutic opportunities.

Yang G, Li C, Tao F, Liu Y, Zhu M, Du Y Genes Dis. 2023; 11(2):645-663.

PMID: 37692513 PMC: 10491877. DOI: 10.1016/j.gendis.2022.12.020.

Transcriptome and methylome sequencing reveals altered long non-coding RNA genes expression and their aberrant DNA methylation in equine sarcoids.

Semik-Gurgul E, Gurgul A, Szmatola T Funct Integr Genomics. 2023; 23(3):268.

PMID: 37552338 PMC: 10409845. DOI: 10.1007/s10142-023-01200-2.

ADAMTS-1 inhibits angiogenesis via the PI3K/Akt-eNOS-VEGF pathway in lung cancer cells.

Wang B, Chen S, Zhao J, Xiang B, Gu X, Zou F Transl Cancer Res. 2022; 8(8):2725-2735.

PMID: 35117030 PMC: 8798392. DOI: 10.21037/tcr.2019.10.34.

In Silico Identification of Contradictory Role of ADAMTS5 in Hepatocellular Carcinoma.

Zhu Z, Xu J, Wu X, Lin S, Li L, Ye W Technol Cancer Res Treat. 2021; 20:1533033820986826.

PMID: 33522433 PMC: 7871357. DOI: 10.1177/1533033820986826.

References

Luque A, Carpizo D, Iruela-Arispe M . ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J Biol Chem. 2003; 278(26):23656-65. DOI: 10.1074/jbc.M212964200. View

Wu E, Croucher P, McKie N . Expression of members of the novel membrane linked metalloproteinase family ADAM in cells derived from a range of haematological malignancies. Biochem Biophys Res Commun. 1997; 235(2):437-42. DOI: 10.1006/bbrc.1997.6714. View

Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, Yoshinaka T . Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002; 8(1):35-40. DOI: 10.1038/nm0102-35. View

Sounni N, Roghi C, Chabottaux V, Janssen M, Munaut C, Maquoi E . Up-regulation of vascular endothelial growth factor-A by active membrane-type 1 matrix metalloproteinase through activation of Src-tyrosine kinases. J Biol Chem. 2004; 279(14):13564-74. DOI: 10.1074/jbc.M307688200. View

Werb Z, Vu T, Rinkenberger J, Coussens L . Matrix-degrading proteases and angiogenesis during development and tumor formation. APMIS. 1999; 107(1):11-8. DOI: 10.1111/j.1699-0463.1999.tb01521.x. View

Moss M, White J, Lambert M, Andrews R . TACE and other ADAM proteases as targets for drug discovery. Drug Discov Today. 2001; 6(8):417-426. DOI: 10.1016/s1359-6446(01)01738-x. View

Kaushal G, Shah S . The new kids on the block: ADAMTSs, potentially multifunctional metalloproteinases of the ADAM family. J Clin Invest. 2000; 105(10):1335-7. PMC: 315473. DOI: 10.1172/JCI10078. View

Maquoi E, Sounni N, Devy L, Olivier F, Frankenne F, Krell H . Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor. Clin Cancer Res. 2004; 10(12 Pt 1):4038-47. DOI: 10.1158/1078-0432.CCR-04-0125. View

Tang B . ADAMTS: a novel family of extracellular matrix proteases. Int J Biochem Cell Biol. 2001; 33(1):33-44. DOI: 10.1016/s1357-2725(00)00061-3. View

10.

Overall C, Lopez-Otin C . Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat Rev Cancer. 2002; 2(9):657-72. DOI: 10.1038/nrc884. View

11.

Masui T, Hosotani R, Tsuji S, Miyamoto Y, Yasuda S, Ida J . Expression of METH-1 and METH-2 in pancreatic cancer. Clin Cancer Res. 2001; 7(11):3437-43. View

12.

Handsley M, Edwards D . Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer. 2005; 115(6):849-60. DOI: 10.1002/ijc.20945. View

13.

Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T . Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg. 2004; 25(3):443-8. DOI: 10.1016/j.ejcts.2003.11.031. View

14.

Cataldo D, Tournoy K, Vermaelen K, Munaut C, Foidart J, Louis R . Matrix metalloproteinase-9 deficiency impairs cellular infiltration and bronchial hyperresponsiveness during allergen-induced airway inflammation. Am J Pathol. 2002; 161(2):491-8. PMC: 1850735. DOI: 10.1016/S0002-9440(10)64205-8. View

15.

Trejo Y, Bordenave R, Beviacqua M, Zanoni L, Rumi L . Tumor necrosis factor-alfa production by monocytes from lung and colorectal cancer patients. J Exp Clin Cancer Res. 2001; 20(1):71-3. View

16.

Rosendahl M, Ko S, Long D, Brewer M, Rosenzweig B, Hedl E . Identification and characterization of a pro-tumor necrosis factor-alpha-processing enzyme from the ADAM family of zinc metalloproteases. J Biol Chem. 1997; 272(39):24588-93. DOI: 10.1074/jbc.272.39.24588. View

17.

Iba K, Albrechtsen R, Gilpin B, Frohlich C, Loechel F, Zolkiewska A . The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. J Cell Biol. 2000; 149(5):1143-56. PMC: 2174829. DOI: 10.1083/jcb.149.5.1143. View

18.

Kuno K, Kanada N, Nakashima E, Fujiki F, ICHIMURA F, Matsushima K . Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. J Biol Chem. 1997; 272(1):556-62. DOI: 10.1074/jbc.272.1.556. View

19.

Horiuchi K, Weskamp G, Lum L, Hammes H, Cai H, Brodie T . Potential role for ADAM15 in pathological neovascularization in mice. Mol Cell Biol. 2003; 23(16):5614-24. PMC: 166329. DOI: 10.1128/MCB.23.16.5614-5624.2003. View

20.

Iruela-Arispe M, Carpizo D, Luque A . ADAMTS1: a matrix metalloprotease with angioinhibitory properties. Ann N Y Acad Sci. 2003; 995:183-90. DOI: 10.1111/j.1749-6632.2003.tb03221.x. View